{
  "company": {
    "name": "Imvax",
    "website": "https://imvax.com/",
    "record": "https://startuphistory.org/c/imvax.com"
  },
  "status": null,
  "history_since": "2013-12-31T17:09:26.000Z",
  "baseline": {
    "snapshot_id": "01e6443a320359f54a2ac1fc38244a27148156918f93fc6f3a46957539dface1",
    "observed_at": "2020-05-02T12:28:46.000Z",
    "headline": "TRANSFORMING CANCER OUTCOMES ™",
    "description": "Imvax™ is a clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers wit",
    "evidence": "https://web.archive.org/web/20200502122846/https://www.imvax.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-06T17:22:41.701Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2020-05-02T12:28:46.000Z",
      "variants": [
        {
          "headline": "TRANSFORMING CANCER OUTCOMES ™",
          "subhead": "Imvax™ is a clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers wit",
          "observed_at": "2020-05-02T12:28:46.000Z",
          "evidence": "https://web.archive.org/web/20200502122846/https://www.imvax.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "TRANSFORMING CANCER OUTCOMES ™",
      "subhead": "Imvax™ is a clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers wit",
      "from": "2020-05-02T12:28:46.000Z",
      "to": "2020-05-02T12:28:46.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20200502122846/https://www.imvax.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2020-05-02T12:28:46.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-06T17:22:41.701Z",
      "variants": [
        {
          "headline": "Turning the complexity of solid tumors against them",
          "subhead": "Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.",
          "observed_at": "2022-01-18T21:35:33.000Z",
          "evidence": "https://web.archive.org/web/20220118213533/https://www.imvax.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Turning the complexity of solid tumors against them",
          "subhead": "Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.",
          "observed_at": "2022-07-03T20:28:43.000Z",
          "evidence": "https://web.archive.org/web/20220703202843/https://www.imvax.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Turning the complexity of a solid tumor against itself",
          "subhead": "Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.",
          "observed_at": "2023-09-07T21:38:27.000Z",
          "evidence": "https://web.archive.org/web/20230907213827/https://www.imvax.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Turning the complexity of a solid tumor against itself",
          "subhead": "Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.",
          "observed_at": "2024-07-02T19:44:06.000Z",
          "evidence": "https://web.archive.org/web/20240702194406/https://www.imvax.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Turning the complexity of a solid tumor against itself",
          "subhead": "Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.",
          "observed_at": "2025-07-09T09:10:43.000Z",
          "evidence": "https://web.archive.org/web/20250709091043/https://www.imvax.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Turning the complexity of a solid tumor against itself",
          "subhead": "Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.",
          "observed_at": "2026-09-29T07:28:02.000Z",
          "evidence": "https://web.archive.org/web/20260929072802/https://www.imvax.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Turning the complexity of a solid tumor against itself",
          "subhead": "Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.",
          "observed_at": "2026-11-06T17:22:41.701Z",
          "evidence": "https://www.imvax.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Turning the complexity of a solid tumor against itself",
      "subhead": "Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.",
      "from": "2022-01-18T21:35:33.000Z",
      "to": "2026-11-06T17:22:41.701Z",
      "captures": 7,
      "evidence": "https://www.imvax.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2022-01-18T21:35:33.000Z",
          "to": "2026-11-06T17:22:41.701Z"
        }
      },
      "current": true
    }
  ],
  "changes": [],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Imvax” company record, https://startuphistory.org/c/imvax.com"
}